Coronary disease articles

La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

Balancing Bleeding Risk vs. Thrombotic Risk to Define Dual Antiplatelet Therapy Duration

Balancing Bleeding Risk vs. Thrombotic Risk to Define Dual Antiplatelet Therapy Duration

Patients who undergo complex angioplasty are at higher ischemic risk, but only benefit from extended dual antiplatelet therapy if there are no factors for high bleeding risk. These data suggest that the bleeding risk must weigh more than the ischemic risk on the determination of dual antiplatelet therapy duration. Complex angioplasty is associated with higher

Costos hospitalarios y de las complicaciones de las oclusiones totales crónicas

In-Hospital Costs and Costs of Complications of Chronic Total Occlusions

Is a chronic total occlusion worth rechanneling? This question can often be found in different studies, all of them with clinical endpoints. This study (soon to be published in J Am Coll Cardiol Intv.) analyzes another aspect: costs, not only derived from materials used for a successful procedure, but also from materials and hospital stay

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

DES and DCB with Similar Results in Femoropopliteal Artery Disease

Courtesy of Dr. Carlos Fava. Nowadays, peripheral interventions are on the rise and the technological development of stents and balloons would help achieve better outcomes. Both drug-eluting stents (DES) and drug-coated balloons (DCB) have proved to be beneficial for femoropopliteal interventions, but the actual role of each of these technologies remains unclear. This prospective, randomized 1:1

ACC 2019 | Infartarse muy joven o 10 años después no cambia la mortalidad a largo plazo

ACC 2019 | Having an Infarction at Very Young Age or 10 Years Later Does Not Change Long-Term Mortality

Patients who suffered their first coronary event before turning 40 years old have similar long-term mortality to those who experienced it even 10 years later, according to the YOUNG-MI Registry presented at the American College of Cardiology [ACC] 2019 Scientific Sessions. Secondary prevention must be used aggressively in both young and elder patients.   Over more than

ACC 2019 | SAFARI: sorpresivamente, el acceso radial no ofrece ventajas en el infarto

ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI

This study was not able to show benefits in terms of mortality or bleeding when using radial vs. femoral approach in patients undergoing ST elevation myocardial Infarction. This small trial does not change things for “radialists” way past their learning curve who already feel confident with this technique. For them, there is no way back.

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

Drug eluting Stents vs. Drug Coated Balloons for In-Stent Restenosis

The rationale behind the decision to not add another layer of metal to the artery sounded attractive and this was what paved the way for drug coated balloons as an alternative strategy to treat in-stent restenosis. “We’ve already got a stent in place, we only have to dilate and leave the drug” is what we

reserva fraccional de flujo

Angiography-Derived FFR: Complicated Software or Imminent Reality?

Angiography-derived fractional flow reserve (FFR) demonstrated substantial usefulness, especially in patients with three-vessel lesions. The functional SYNTAX score derived from angiography has the potential to redefine prognosis and treatment strategies compared with the classic anatomical SYNTAX score. This study sought to investigate the applicability of this method in patients with multivessel lesions included in the

La recanalización de las CTO mejora la calidad de vida

CTO: in Radial Access with Similar Results to Femoral

Courtesy of Dr. Carlos Fava. One of the characteristics of chronic total occlusion (CTO) is the use of two access routes: femoral and radial. The radial approach is safer, but it has not been thoroughly analyzed in this type of PCI. The study looked at 3709 patients undergoing left main percutaneous coronary intervention (PCI) for

La enfermedad coronaria funciona como un predictor a 30 días en el TAVI

Asymptomatic Coronary Artery Disease, Silent Ischemia: A Cardiologist’s Headache

We need more evidence to guide us in the management of silent ischemia. Confirmed asymptomatic coronary artery disease is a problem for cardiologists, who lack enough evidence to guide a risk-benefit assessment that justifies revascularization. Revascularizing the outcome of a functional assessment may reduce the rates of death and infarction, or it may just be

stent

Abluminal Sirolimus and luminal CD34 antibody layer: Is COMBO the Future of Stents?

This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Revascularization in Patients with Multivessel Disease, Diabetes, and Kidney Disease

According to this new study, in patients with coronary disease, diabetes, and chronic kidney disease who underwent revascularization through angioplasty or surgery, events are similar. This is one of the first studies painting the real picture for the prognosis of patients revascularized in these conditions (diabetes plus chronic kidney disease).   At first sight, these

Top